secwatch.observer — SEC 8-K summary
======================================

Issuer:     Keros Therapeutics, Inc. (KROS)
CIK:        0001664710
Form:       8-K
Filed at:   2023-03-03T23:59:59+00:00
Accession:  0001664710-23-000020
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Keros Therapeutics reports Q4 2022 net loss of $29.7M; cash runway into Q3 2025
-------------------------------------------------------------------------------

- Net loss of $29.7M for Q4 2022 vs $6.9M in Q4 2021; full year net loss $104.7M vs $58.7M.
- No revenue in 2022; 2021 revenue of $20.1M from Hansoh license agreement.
- R&D expenses $24.9M in Q4 2022, up from $18.8M; driven by Phase 2 trials of KER-050.
- Cash and equivalents $279.0M at Dec 31, 2022; with ATM proceeds, funds operations into Q3 2025.
- Anticipated 2023 milestones: complete MDS trial enrollment, report additional data for KER-050, KER-047, KER-012.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1664710/000166471023000020/0001664710-23-000020-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1664710/000166471023000020/kros-20230303.htm
  HTML page:      https://secwatch.observer/filing/0001664710-23-000020

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer